Summit Therapeutics plc Stock
Your prediction
Pros and Cons of Summit Therapeutics plc in the next few years
Pros
?
S********** s********
?
C******** o* t** e**********
?
G***** c******* t* c**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Summit Therapeutics plc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Summit Therapeutics plc | - | - | - | - | - | - | - |
| Proteome Sciences | 53.570% | 2.381% | 330.000% | 7.500% | -25.862% | -34.848% | -27.119% |
| Oxford BioMedica PLC | - | 3.597% | 5.109% | 41.176% | 41.176% | 72.249% | -22.953% |
| Sareum Holdings plc | - | 0.000% | -6.383% | -56.291% | -56.291% | -84.561% | - |
News
2 Stocks Up Over 600% in the Past 3 Years With More Room to Run
Those who had the foresight to invest in Summit Therapeutics (NASDAQ: SMMT) and Madrigal Pharmaceuticals (NASDAQ: MDGL) three years ago are sitting pretty right now. Both companies have soared over
Why a $27 Million Buy Signals New Confidence in Weatherford Stock
Summit Street Capital Management established a new position in Weatherford International (NASDAQ:WFRD), adding 398,661 shares valued at an estimated $27.3 million during the third quarter, according
Signet Jewelers Gains New $25 Million Institutional Backer — Is the Stock a Buy?
On November 14, New York City-based Summit Street Capital Management disclosed a new position in Signet Jewelers (NYSE:SIG), acquiring 264,054 shares valued at $25.3 million, according to its latest